These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37201046)

  • 1. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
    Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
    J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
    Yu W; Tao Q; Zhang Y; Yi F; Feng L
    J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
    Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
    EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
    Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
    Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
    Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
    Front Oncol; 2021; 11():754881. PubMed ID: 34692541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
    Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
    Front Oncol; 2022; 12():841977. PubMed ID: 35371995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study.
    Zhang W; Zhang Z; Lou S; Li D; Ma Z; Xue L
    Front Oncol; 2022; 12():929342. PubMed ID: 36119532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 17. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
    Dong Q; Diao Y; Sun X; Zhou Y; Ran J; Zhang J
    BMJ Open; 2022 Apr; 12(4):e049992. PubMed ID: 35379611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of radiotherapy combined with anti-angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer.
    Zhai M; Zhang Z; Wang H; Ren J; Zhang S; Li M; Liu L; Li L; Zhang L; Li X; Zhang T; Lin Z
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38112050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.